{"id":11916,"date":"2014-05-27T17:33:42","date_gmt":"2014-05-27T16:33:42","guid":{"rendered":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/"},"modified":"2016-04-21T18:01:08","modified_gmt":"2016-04-21T17:01:08","slug":"medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica","status":"publish","type":"post","link":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/","title":{"rendered":"Medicamentos biosimilares – Aspectos a considerar en una regulaci\u00f3n espec\u00edfica"},"content":{"rendered":"

CEFI, Centro de Estudios para el Fomento de la Investigaci\u00f3n, ha organitzat aquest Seminari a fi de tractar diverses q\u00fcestions d\u2019actualitat en relaci\u00f3 amb la normativa aplicable als medicaments biol\u00f2gics.<\/p>\n

L\u2019acte ha estat inaugurat per Maria Alonso Burgaz, Presidenta de CEFI i per Regina Revilla Pedreira, Presidenta d\u2019Asebio.<\/p>\n

A la seva intervenci\u00f3, Jordi Faus s\u2019ha pronunciat a favor de la preparaci\u00f3 d\u2019una norma que regula de forma espec\u00edfica diversos aspectes relacionats amb els medicaments biol\u00f2gics, recordant que la Llei 29\/2006 ja preveu aquesta possibilitat al seu article 45.<\/p>\n

Dita regulaci\u00f3, en opini\u00f3 de Jordi Faus, s\u2019hauria de recolzar en un an\u00e0lisi rigor\u00f3s dels aspectes cient\u00edfics i m\u00e8dics i prendre en consideraci\u00f3 la posici\u00f3 dels pacients, dels professionals sanitaris, dels encarregats de gestionar la prestaci\u00f3 i tamb\u00e9 dels prove\u00efdors; i hauria tamb\u00e9 d\u2019abordar, amb rigor i finesa, q\u00fcestions que actualment es troben disperses en diferents textos legals amb l\u2019objectiu d\u2019aportar seguretat jur\u00eddica a aquesta mat\u00e8ria tan complexa.<\/p>\n","protected":false},"excerpt":{"rendered":"

CEFI, Centro de Estudios para el Fomento de la Investigaci\u00f3n, ha organitzat aquest Seminari a fi de tractar diverses q\u00fcestions d\u2019actualitat en relaci\u00f3 amb la normativa aplicable als medicaments biol\u00f2gics. L\u2019acte ha estat inaugurat per Maria Alonso Burgaz, Presidenta de CEFI i per Regina Revilla Pedreira, Presidenta d\u2019Asebio. A la seva intervenci\u00f3, Jordi Faus s\u2019ha… <\/p>\n

<\/div>\n

M\u00e9s informaci\u00f3<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[339,331,319],"tags":[],"coauthors":[],"class_list":["post-11916","post","type-post","status-publish","format-standard","hentry","category-biosimilars-dret-farmaceutic-i-life-sciences-ca","category-dret-farmaceutic-i-life-sciences-ca","category-publicacions"],"acf":[],"yoast_head":"\nMedicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner\" \/>\n<meta property=\"og:description\" content=\"CEFI, Centro de Estudios para el Fomento de la Investigaci\u00f3n, ha organitzat aquest Seminari a fi de tractar diverses q\u00fcestions d\u2019actualitat en relaci\u00f3 amb la normativa aplicable als medicaments biol\u00f2gics. L\u2019acte ha estat inaugurat per Maria Alonso Burgaz, Presidenta de CEFI i per Regina Revilla Pedreira, Presidenta d\u2019Asebio. A la seva intervenci\u00f3, Jordi Faus s\u2019ha... M\u00e9s informaci\u00f3\" \/>\n<meta property=\"og:url\" content=\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\" \/>\n<meta property=\"og:site_name\" content=\"Faus Moliner\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-27T16:33:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-04-21T17:01:08+00:00\" \/>\n<meta name=\"author\" content=\"Jordi Faus\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Jordi Faus\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n\t<meta name=\"twitter:label3\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data3\" content=\"Jordi Faus\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\"},\"author\":{\"name\":\"Jordi Faus\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260\"},\"headline\":\"Medicamentos biosimilares – Aspectos a considerar en una regulaci\u00f3n espec\u00edfica\",\"datePublished\":\"2014-05-27T16:33:42+00:00\",\"dateModified\":\"2016-04-21T17:01:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\"},\"wordCount\":188,\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"articleSection\":[\"Biosimilars\",\"Dret farmac\u00e8utic i \u201clife sciences\u201d\",\"Publicacions\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\",\"url\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\",\"name\":\"Medicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner\",\"isPartOf\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\"},\"datePublished\":\"2014-05-27T16:33:42+00:00\",\"dateModified\":\"2016-04-21T17:01:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/faus-moliner.com\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicamentos biosimilares – Aspectos a considerar en una regulaci\u00f3n espec\u00edfica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#website\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"name\":\"faus-moliner.com\",\"description\":\"Otro sitio realizado con WordPress\",\"publisher\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/faus-moliner.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#organization\",\"name\":\"Faus Moliner\",\"url\":\"https:\/\/faus-moliner.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"contentUrl\":\"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg\",\"width\":400,\"height\":283,\"caption\":\"Faus Moliner\"},\"image\":{\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/2372042\/admin\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260\",\"name\":\"Jordi Faus\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/f7cb308a9e6d6fe5434c7ca47ff11be5\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g\",\"caption\":\"Jordi Faus\"},\"description\":\"Jordi Faus graduated in Law at the Autonomous University of Barcelona (1986) and obtained a degree in Advanced Legal European Studies at the College of Europe in Bruges, Belgium (1987). He also has completed an Executive Management Programme at IESE Business School, in Barcelona.\",\"sameAs\":[\"https:\/\/faus-moliner.com\/\"],\"url\":\"https:\/\/faus-moliner.com\/ca\/author\/jordi-faus\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/","og_locale":"ca_ES","og_type":"article","og_title":"Medicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner","og_description":"CEFI, Centro de Estudios para el Fomento de la Investigaci\u00f3n, ha organitzat aquest Seminari a fi de tractar diverses q\u00fcestions d\u2019actualitat en relaci\u00f3 amb la normativa aplicable als medicaments biol\u00f2gics. L\u2019acte ha estat inaugurat per Maria Alonso Burgaz, Presidenta de CEFI i per Regina Revilla Pedreira, Presidenta d\u2019Asebio. A la seva intervenci\u00f3, Jordi Faus s\u2019ha... M\u00e9s informaci\u00f3","og_url":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/","og_site_name":"Faus Moliner","article_published_time":"2014-05-27T16:33:42+00:00","article_modified_time":"2016-04-21T17:01:08+00:00","author":"Jordi Faus","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Jordi Faus","Temps estimat de lectura":"1 minut","Written by":"Jordi Faus"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#article","isPartOf":{"@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/"},"author":{"name":"Jordi Faus","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260"},"headline":"Medicamentos biosimilares – Aspectos a considerar en una regulaci\u00f3n espec\u00edfica","datePublished":"2014-05-27T16:33:42+00:00","dateModified":"2016-04-21T17:01:08+00:00","mainEntityOfPage":{"@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/"},"wordCount":188,"publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"articleSection":["Biosimilars","Dret farmac\u00e8utic i \u201clife sciences\u201d","Publicacions"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/","url":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/","name":"Medicamentos biosimilares - Aspectos a considerar en una regulaci\u00f3n espec\u00edfica - Faus Moliner","isPartOf":{"@id":"https:\/\/faus-moliner.com\/en\/#website"},"datePublished":"2014-05-27T16:33:42+00:00","dateModified":"2016-04-21T17:01:08+00:00","breadcrumb":{"@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/faus-moliner.com\/ca\/medicamentos-biosimilares-aspectos-considerar-una-regulacion-especifica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/faus-moliner.com\/ca\/"},{"@type":"ListItem","position":2,"name":"Medicamentos biosimilares – Aspectos a considerar en una regulaci\u00f3n espec\u00edfica"}]},{"@type":"WebSite","@id":"https:\/\/faus-moliner.com\/en\/#website","url":"https:\/\/faus-moliner.com\/en\/","name":"faus-moliner.com","description":"Otro sitio realizado con WordPress","publisher":{"@id":"https:\/\/faus-moliner.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/faus-moliner.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/faus-moliner.com\/en\/#organization","name":"Faus Moliner","url":"https:\/\/faus-moliner.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/","url":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","contentUrl":"https:\/\/faus-moliner.com\/wp-content\/uploads\/2023\/03\/Logo-FM-web.jpg","width":400,"height":283,"caption":"Faus Moliner"},"image":{"@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/2372042\/admin\/"]},{"@type":"Person","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/da4b76d949932369d90eaa21ed440260","name":"Jordi Faus","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/faus-moliner.com\/en\/#\/schema\/person\/image\/f7cb308a9e6d6fe5434c7ca47ff11be5","url":"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/896c20951cba2f462a35f9a554d612f00999b71a73a0ad6a1625c27912d34e52?s=96&d=mm&r=g","caption":"Jordi Faus"},"description":"Jordi Faus graduated in Law at the Autonomous University of Barcelona (1986) and obtained a degree in Advanced Legal European Studies at the College of Europe in Bruges, Belgium (1987). He also has completed an Executive Management Programme at IESE Business School, in Barcelona.","sameAs":["https:\/\/faus-moliner.com\/"],"url":"https:\/\/faus-moliner.com\/ca\/author\/jordi-faus\/"}]}},"_links":{"self":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts\/11916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/comments?post=11916"}],"version-history":[{"count":0,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/posts\/11916\/revisions"}],"wp:attachment":[{"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/media?parent=11916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/categories?post=11916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/tags?post=11916"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/faus-moliner.com\/ca\/wp-json\/wp\/v2\/coauthors?post=11916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}